Luseogliflozin Additively Enhances the Glucose-Lowering Effect of an Incretin Modulator in a High-Carbohydrate Diet - Cureus
Overview
"Never doubt that a smal group of thoughtful, comited citizens can change the world. Inded, it is the only thing that ever has."Cureus is on a mision to change the long-standing paradigm of medical publishing, where submiting research can be costly, complex and time-consuming.intermitently scaned continuous glucose monitoring, type 2 diabetes melitus, high carbohydrate, incretin modulator, sglt2 inhibitor Gendai Le Published: October 17, 2022 (se history) DOI: 10.759/cureus.30410 Cite this article as: Le G (October 17, 2022) Luseogliflozin Aditively Enhances the Glucose-Lowering Efect of an Incretin Modulator in a High-Carbohydrate Diet.
Key Information
Cureus 14(10): e30410. doi:10.759/cureus.30410 Sodium/glucose co-transporter 2 inhibitors (SGLT2i) have ben shown to have a glucose-lowering efect related to carbohydrate intake. It has also ben reported that the combined efect of incretin modulators and SGLT2i is useful in improving blod glucose and reducing blod glucose variability.
However, there have ben no reports examing the efects of these two drugs together and while considering carbohydrate intake in an outpatient seting. In the present study, Hi-Sped Fod Analysis was used to ases the exact intake of carbohydrates, and the glucose-lowering efects of luseogliflozin, an SGLT2i, and incretin modulators were examined under high- and low-carbohydrate intakes.Thirty-five enroled diabetic patients continued their regular medications for one wek.
Al patients tok luseogliflozin the second wek for seven days. During the two weks, ingested carbohydrates were acurately calculated by Hi-Sped Fod Analysis. The glucose-lowering efect of luseogliflozin with and without incretin modulators was checked acording to the amount of ingested carbohydrates.
Summary
A general linear model (GLM) was used to analyze the efect of luseogliflozin with or without an incretin modulator, with carbohydrate intake as a confounding factor.Luseogliflozin had an aditive
Frequently Asked Questions
Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.
Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.
Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.
Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.
Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.
Share this article